Your browser is no longer supported. Please, upgrade your browser.
Settings
TNXP Tonix Pharmaceuticals Holding Corp. daily Stock Chart
TNXP [NASD]
Tonix Pharmaceuticals Holding Corp.
Index- P/E- EPS (ttm)-81.02 Insider Own0.06% Shs Outstand48.63M Perf Week-28.28%
Market Cap34.53M Forward P/E- EPS next Y-1.52 Insider Trans259.10% Shs Float48.63M Perf Month-47.79%
Income-31.10M PEG- EPS next Q-0.42 Inst Own2.10% Short Float3.82% Perf Quarter-37.72%
Sales- P/S- EPS this Y92.80% Inst Trans- Short Ratio0.19 Perf Half Y-82.05%
Book/sh1.52 P/B0.47 EPS next Y13.20% ROA-201.00% Target Price2.50 Perf Year-97.17%
Cash/sh0.23 P/C3.08 EPS next 5Y- ROE-249.20% 52W Range0.39 - 31.40 Perf YTD-39.32%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-97.96% Beta1.31
Dividend %- Quick Ratio2.70 Sales past 5Y- Gross Margin- 52W Low64.53% ATR0.23
Employees16 Current Ratio2.70 Sales Q/Q- Oper. Margin- RSI (14)43.07 Volatility16.50% 21.04%
OptionableNo Debt/Eq0.00 EPS Q/Q97.00% Profit Margin- Rel Volume0.20 Prev Close0.71
ShortableNo LT Debt/Eq0.00 EarningsMar 23 Payout- Avg Volume9.94M Price0.64
Recom2.00 SMA20-19.25% SMA50-30.50% SMA200-82.87% Volume1,535,133 Change-9.58%
Apr-18-19Upgrade ROTH Capital Neutral → Buy $4
Aug-18-17Upgrade ROTH Capital Neutral → Buy $6
Sep-07-16Downgrade ROTH Capital Buy → Neutral
Feb-17-16Reiterated Oppenheimer Outperform $18 → $10
Nov-04-15Initiated Cantor Fitzgerald Buy
Jun-12-15Initiated Oppenheimer Outperform $18
Feb-17-15Reiterated ROTH Capital Buy $10 → $12
Sep-29-14Reiterated ROTH Capital Buy $17 → $10
Mar-24-20 05:15PM  Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights GlobeNewswire +16.07%
Mar-23-20 04:30PM  Tonix Pharmaceuticals to Deliver Virtual Presentation for Spring Investor Summit GlobeNewswire -12.07%
Mar-16-20 10:42AM  8 Biotechs With Coronavirus Vaccines In Development Benzinga -17.19%
Mar-03-20 05:00PM  Tonix Pharmaceuticals Holding Corp. Closes $16,005,000 Common Stock Registered Direct Offering GlobeNewswire -13.97%
Feb-28-20 08:45AM  Tonix Pharmaceuticals, Inc. Prices $16,005,000 Common Stock Offering Priced At-The-Market GlobeNewswire -37.57%
Feb-27-20 09:21AM  Southern Research collaborating to develop coronavirus vaccine American City Business Journals +92.22%
Feb-26-20 09:36AM  The Daily Biotech Pulse: Menlo Flunks Midstage Trial, GW Pharma's Earnings, COVID-19 Updates Benzinga +122.55%
07:00AM  Tonix Pharmaceuticals Announces Research Collaboration with Southern Research to Develop a Potential Vaccine to Protect Against New Coronavirus Disease 2019 (COVID-19) Based on Horsepox Virus (TNX-1800) GlobeNewswire
Feb-11-20 04:01PM  Tonix Pharmaceuticals Announces Closing of $7.5 million Public Offering GlobeNewswire
Feb-07-20 08:45AM  Tonix Pharmaceuticals Prices $7.5 million Public Offering GlobeNewswire -38.85%
07:32AM  The Daily Biotech Pulse: Assertio To Sell Opioid Pain Drug, Milestone Payment For Aduro, Myriad Genetics CEO Resigns Benzinga
Feb-06-20 07:47AM  The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs Benzinga -48.82%
Feb-05-20 05:15PM  Tonix Pharmaceuticals Announces Outcome of Interim Analysis for Phase 3 RECOVERY Study of Tonmya® (TNX-102 SL) in PTSD GlobeNewswire
Feb-04-20 07:00AM  Tonix Pharmaceuticals to Participate in Upcoming February Investor Conferences GlobeNewswire +17.27%
Jan-30-20 09:26AM  The Daily Biotech Pulse: Sanofi Reports Positive Readout, Tonix Vaccine Candidate Aces Animal Study, Hologix's Weak Guidance Benzinga
Jan-29-20 04:15PM  Tonix Pharmaceuticals Presented Results from a Preclinical Study of TNX-801, a Potential Vaccine to Prevent Smallpox and Monkeypox, in a Poster Presentation at the 2020 American Society for Microbiology (ASM) Biothreats Conference GlobeNewswire -9.87%
01:04PM  Does The Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Share Price Tend To Follow The Market? Simply Wall St.
Jan-27-20 09:51AM  Company News for Jan 27, 2020 Zacks
Jan-24-20 07:00AM  Tonix Pharmaceuticals Announces Successful Completion of a Fed-Fasting and Dose Proportionality Study of TNX-102 SL GlobeNewswire +17.27%
Jan-23-20 07:00AM  Tonix Pharmaceuticals to Present Results from Preclinical Study of TNX-801 in a Poster Presentation at the 2020 American Society for Microbiology (ASM) Biothreats Conference GlobeNewswire +6.11%
Jan-07-20 07:00AM  Tonix Pharmaceuticals to Present at Biotech Showcase 2020 GlobeNewswire +5.16%
Dec-16-19 03:15PM  Tonix Pharmaceuticals Announces Plan to Develop TNX-601 CR Tablets for Once-Daily Treatment of Major Depressive Disorder, in Addition to PTSD, After Successful Completion of Phase 1 Pharmacokinetic Study GlobeNewswire +7.83%
07:20AM  TNXP: TNX-102 SL P3 PTSD Trial Interim Readout in 1Q20; P3 Trial in Fibromyalgia Underway Zacks Small Cap Research
Dec-13-19 09:23AM  Company News for Dec 13, 2019 Zacks
Dec-11-19 04:05PM  Tonix Pharmaceuticals Announces New European Patent for the Composition and Formulation of TNX-102 SL GlobeNewswire +7.85%
Dec-10-19 07:00AM  Tonix Pharmaceuticals Enrolls First Patient in Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia GlobeNewswire -6.88%
Dec-04-19 07:00AM  Tonix Pharmaceuticals to Present at 12th Annual LD Micro Main Event GlobeNewswire
Dec-03-19 07:00AM  Tonix Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement GlobeNewswire -6.61%
Nov-26-19 04:05PM  Tonix Pharmaceuticals Announces Receipt of FDA Official Minutes from Breakthrough Therapy Type B Clinical Guidance Meeting for Tonmya® as a Potential New Treatment for PTSD GlobeNewswire -16.00%
Nov-25-19 04:05PM  Tonix Pharmaceuticals to Participate in Benchmarks Annual Discovery 1x1 Conference GlobeNewswire
Nov-22-19 08:18AM  The Daily Biotech Pulse: Roche-Spark Deal Extended Again, Zymeworks' Positive Readout, Enanta Misses Earnings Estimate Benzinga
Nov-21-19 09:40AM  Tonix Plans Regulatory Filing To Kick Off Study Of Alcohol Use Disorder Drug Benzinga -13.70%
08:00AM  Tonix Pharmaceuticals Announces Initiation of the Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia GlobeNewswire
07:22AM  The Daily Biotech Pulse: Patent Win For Cellectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon Benzinga
Nov-20-19 04:05PM  Tonix Pharmaceuticals Completes Pre-IND Meeting with FDA for TNX-102 SL as a Clinical Candidate for Alcohol Use Disorder GlobeNewswire
07:00AM  Tonix Pharmaceuticals Announces Closing of $9.0 Million Public Offering GlobeNewswire
Nov-15-19 08:30AM  Tonix Pharmaceuticals Prices $9.0 Million Public Offering GlobeNewswire -25.34%
Nov-08-19 04:45PM  Tonix Pharmaceuticals Reports Third Quarter 2019 Financial Results and Operational Highlights GlobeNewswire
Nov-04-19 07:00AM  Tonix Pharmaceuticals Announces 12-Week Primary Endpoint and Addition of Adaptive Design Features in the Currently-Enrolling Phase 3 RECOVERY Study of Tonmya® for PTSD, Following FDA Meeting GlobeNewswire -16.07%
Oct-31-19 01:00PM  Tonix Pharmaceuticals Announces 1-for-10 Reverse Stock Split GlobeNewswire -15.63%
Oct-30-19 03:49PM  Companies Like Tonix Pharmaceuticals Holding (NASDAQ:TNXP) Can Be Considered Quite Risky Simply Wall St.
Oct-23-19 07:54AM  The Daily Biotech Pulse: Eli Lily Revenues Trail Estimates, Moderna Gets Fast Track Designation, MacroGenics' Lukewarm Breast Cancer Data Benzinga +5.72%
07:00AM  Tonix Pharmaceuticals Announces Issuance of U.S. Patent for Crystalline Tianeptine Oxalate Salt, the Active Ingredient of TNX-601 GlobeNewswire
Oct-15-19 07:00AM  Tonix Pharmaceuticals Joins the Alliance for Biosecurity GlobeNewswire +6.91%
Oct-07-19 07:00AM  Tonix Pharmaceuticals Announces that the European Patent Office Opposition Division Has Upheld Its Patent for the Use of the Active Ingredient in TNX-102 SL, Cyclobenzaprine, for the Treatment of PTSD GlobeNewswire
Oct-03-19 08:00AM  Tonix Pharmaceuticals Announces Completion of Long-Term Exposure Studies in Participants with PTSD to Evaluate the Tolerability of TNX-102 SL 5.6 mg GlobeNewswire
Sep-19-19 09:30AM  TNXP: TNX-102 SL P3 PTSD Trial Enrolling; Pipeline Expansion Adds Phase 2 Program and Two Pre-Clinical Programs Zacks Small Cap Research
Sep-17-19 07:23AM  The Daily Biotech Pulse: Acceleron Shelves Muscular Dystrophy Drug Trial, Aclaris Aces Late-Stage Study Benzinga +5.45%
Sep-16-19 04:15PM  Tonix Pharmaceuticals Announces Licensing Agreement with Columbia University for the Development of Recombinant Trefoil Family Factor 2 (rTFF2), or TNX-1700, for the Treatment of Gastric and Pancreatic Cancers GlobeNewswire
07:00AM  Tonix Pharmaceuticals Announces Publication of Paper on Triple Reuptake Inhibitor TNX-1600 (formerly D-578) in the European Journal of Pharmacology GlobeNewswire
Sep-12-19 07:00AM  Tonix Pharmaceuticals to Speak at the 2019 Annual National Association of Veterans Research and Education Foundations (NAVREF) Conference GlobeNewswire
Sep-10-19 07:00AM  Tonix Pharmaceuticals to Present at Upcoming September Investor Conferences GlobeNewswire -5.46%
Sep-04-19 07:00AM  Tonix Pharmaceuticals Doses Participants in Phase 1 Study Evaluating TNX-601 for the Daytime Treatment of Posttraumatic Stress Disorder GlobeNewswire
Aug-28-19 12:44PM  Should You Take Comfort From Insider Transactions At Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)? Simply Wall St.
Aug-21-19 07:00AM  Tonix Pharmaceuticals and Massachusetts General Hospital Enter into Research Collaboration to Develop Tonixs Third Generation Anti-CD154 Monoclonal Antibody, TNX-1500, for the Treatment and Prevention of Organ Transplant Rejection GlobeNewswire
Aug-20-19 07:00AM  Tonix Pharmaceuticals Expands Preclinical Pipeline with Triple Reuptake Inhibitor, TNX-1600, for the Treatment of PTSD GlobeNewswire +8.89%
Aug-12-19 08:00AM  Tonix Pharmaceuticals Reports Second Quarter 2019 Financial Results and Operational Highlights GlobeNewswire
Aug-02-19 04:05PM  Tonix Pharmaceuticals Announces Director Stepping Down GlobeNewswire
Jul-25-19 07:00AM  Tonix Pharmaceuticals Announces Issuance of U.S. Patent for the Composition and Formulation of TNX-102 SL GlobeNewswire
Jul-18-19 04:05PM  Tonix Pharmaceuticals Announces Closing of Public Offering of Common Stock GlobeNewswire
Jul-16-19 08:30AM  Tonix Pharmaceuticals Announces Pricing of Public Offering of Common Stock GlobeNewswire -40.66%
Jun-13-19 07:00AM  Tonix Pharmaceuticals Announces Issuance of Patent in China for the Composition and Formulation of TNX-102 SL GlobeNewswire
Jun-10-19 01:05PM  TNXP: Enrollment Continues for Phase 3 Trial of TNX-102 SL in PTSD Zacks Small Cap Research
May-30-19 08:00AM  Tonix Pharmaceuticals Presented Results from Pharmacokinetic Analyses of TNX-102 SL in a Poster Presentation at the American Society of Clinical Psychopharmacology GlobeNewswire
May-28-19 04:15PM  Tonix Pharmaceuticals to Present at BIO 2019 International Convention GlobeNewswire -8.87%
07:43AM  How Does Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Affect Your Portfolio Volatility? Simply Wall St.
May-23-19 07:00AM  Tonix Pharmaceuticals Expands Pipeline with Mid-Stage Biologic Candidate TNX-1300 for Cocaine Intoxication GlobeNewswire -6.40%
May-21-19 04:15PM  Tonix Pharmaceuticals Will Present Results from Pharmacokinetic Analyses of TNX-102 SL in a Poster Presentation at the American Society of Clinical Psychopharmacology GlobeNewswire +9.62%
May-17-19 04:05PM  Tonix Pharmaceuticals Announces Director Stepping Down GlobeNewswire
May-13-19 08:00AM  Tonix Pharmaceuticals Reports First Quarter 2019 Financial Results and Operational Highlights GlobeNewswire -9.50%
May-08-19 07:00AM  Tonix Pharmaceuticals Announces New Board Member, Daniel Goodman, M.D., MBA GlobeNewswire
Apr-23-19 01:51PM  Tonix Pharmaceuticals Announces Update on the Collaborative Research and Development Agreement (CRADA) with the U.S. Army Medical Materiel Development Activity (USAMMDA) GlobeNewswire
Apr-22-19 07:00AM  Tonix Pharmaceuticals Announces that Breakthrough Therapy Designation Remains in Effect for Tonmya® for the Treatment of Posttraumatic Stress Disorder GlobeNewswire
Apr-19-19 06:49AM  Tonix Pharmaceuticals R&D pact with U.S. Army to be terminated 'without cause' MarketWatch
Apr-10-19 01:45PM  TNXP: Phase 3 Trial of TNX-102 SL in PTSD Underway Zacks Small Cap Research
Apr-04-19 02:35PM  Four Healthcare Stocks Heating Up on Thursday ACCESSWIRE +20.60%
10:21AM  What's Driving The Rally In Nanocap Biotech Tonix Pharma? Benzinga
07:30AM  Tonix Pharmaceuticals Plans to Expand TNX-102 SL Phase 3 Program Beyond PTSD to Include Fibromyalgia GlobeNewswire
Mar-25-19 08:00AM  Tonix Pharmaceuticals to Present at Upcoming Investor Conferences GlobeNewswire
Mar-18-19 08:00AM  Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Operational Highlights GlobeNewswire
Mar-12-19 07:30AM  Tonix Pharmaceuticals to Participate at Upcoming Investor Conferences GlobeNewswire -11.87%
Mar-11-19 09:35AM  Four Healthcare Stocks Making Moves on Monday ACCESSWIRE +20.36%
07:00AM  Tonix Pharmaceuticals Enrolls First Participant in the RECOVERY Study -- a New Phase 3 Trial of Tonmya® for the Treatment of Posttraumatic Stress Disorder GlobeNewswire
Mar-08-19 01:35PM  Four Healthcare Stocks Surpassing Investor Expectations ACCESSWIRE +30.84%
Mar-07-19 04:15PM  Tonix Pharmaceuticals Announces New European Use Patent for TNX-601 GlobeNewswire +19.55%
Mar-01-19 05:41PM  Tonix Pharmaceuticals Provides Update on Tonmya® for the Treatment of Posttraumatic Stress Disorder GlobeNewswire +6.95%
04:00PM  Tonix Pharmaceuticals Announces Share Repurchase Program GlobeNewswire
Feb-19-19 04:30PM  Tonix Pharmaceuticals Announces New Board Member, James Treco GlobeNewswire
Feb-06-19 12:17PM  How Many Insiders Bought Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Shares? Simply Wall St.
Feb-04-19 08:00AM  Tonix Pharmaceuticals to Present at BIO CEO & Investor Conference GlobeNewswire
Jan-03-19 09:45AM  TNXP: Additional Details Revealed for Phase 3 Trial of TNX-102 SL in PTSD Starting in 1Q19 Zacks Small Cap Research -7.59%
Jan-02-19 07:00AM  Tonix Pharmaceuticals to Present at Upcoming Investor Conferences and Participate in Featured Panel Discussion GlobeNewswire
Dec-18-18 07:00AM  Tonix Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement GlobeNewswire
Dec-11-18 04:00PM  Tonix Pharmaceuticals Announces Closing of $15,000,000 Public Offering GlobeNewswire
Dec-07-18 01:37PM  Nano Cap News: Why Tonix Pharmaceuticals (TNXP) Stock Is Moving Today InvestorPlace -6.67%
10:35AM  Tonix Pharmaceuticals Prices $15,000,000 Public Offering GlobeNewswire
Dec-03-18 07:00AM  Tonix Pharmaceuticals Prepares for Phase III Trial for Tonmya, Analysts Review and Target ACCESSWIRE -22.16%
Nov-29-18 07:00AM  Tonix Pharmaceuticals Announces Additional Details of the New Phase 3 Study of Tonmya® for PTSD, Following Receipt of FDA Minutes GlobeNewswire +83.42%
Nov-27-18 07:00AM  Tonix Pharmaceuticals Announces 1-for-10 Reverse Stock Split GlobeNewswire -8.49%
Nov-21-18 07:35AM  Analysis: Positioning to Benefit within The ONE Group Hospitality, Biofrontera AG Sponsored ADR, Aridis Pharmaceuticals, Universal Logistics, Tonix Pharmaceuticals Holding, and AVROBIO Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense. Its lead product candidate is Tonmyar (TNX-102 SL), a proprietary low-dose cyclobenzaprine and sublingual tablet as a bedtime administration, which is in Phase III development for the treatment of posttraumatic stress disorder (PTSD) and Fibromyalgia; and Phase II development for the treatment of agitation in Alzheimer's disease. The company is also developing TNX-601 (tianeptine oxalate) as a daytime administration for the treatment of PTSD and potential indication -neurocognitive dysfunction associated with corticosteroid use that is in pre-investigational new drug (pre-IND) application stage; and TNX-801, a smallpox-preventing vaccine based on a live synthetic version of horsepox virus, which is in pre-IND application stage. Its product pipeline also includes TNX-701, a biodefense development program for protection from radiation injury. Tonix Pharmaceuticals Holding Corp. has a research collaboration agreement with Massachusetts General Hospital to develop TNX-1500, a humanized monoclonal antibody that targets CD154 for the prevention and treatment of organ transplant rejection; and strategic collaboration with Southern Research Institute to support the development of a vaccine, TNX-1800 to protect against the new coronavirus disease. The company was founded in 2007 and is based in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LEDERMAN SETHChief Executive OfficerDec 03Buy1.1620,00023,18023,267Dec 04 07:00 AM